|Mr. William Joseph Radvak BASc||Exec. Chairman||130.5k||N/A||1963|
|Mr. Paul Anthony Brennan B.Sc., M.Sc.||Pres, CEO & Director||394.1k||N/A||N/A|
|Mr. William J. Adams C.A., CPA, CA, CPA||CFO & Corp. Sec.||265.8k||N/A||1962|
|Dr. Ernest Shing-Yan Wong||Consultant & Advisor||442.01k||N/A||1968|
|Mr. Robert G. Pilz B.Com., C.P.A., BComm, CMA||Consultant||37.5k||34.6k||1966|
|Mr. Brian McAlister||Co-Founder & Advisor||N/A||N/A||N/A|
|Dr. Daniel Mikol M.D., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
NervGen Pharma Corp., a clinical stage biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
NervGen Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.